Healthcare >> Analyst Interviews >> September 13, 2002

Novel Therapeutics In Cancer & Aids: Akhtar Samad – Bear, Stearns & Co

AKHTAR SAMAD is an Equity Research Analyst and Managing Director covering the Biotechnology sector. He was previously a senior biotechnology Analyst at Mehta Partners (formerly Mehta and Isaly), and Head of Healthcare Research at Oscar Gruss and Son. Mr. Samad's scientific background is primarily in the areas of cancer and genomics. He has authored textbook chapters and research papers on cancer and genomics in leading scientific journals, and has organized conferences on cancer and genomics. He was also formerly involved in a collaboration with biopharmaceutical companies to develop a proprietary genomics technology. Mr. Samad holds MD and PhD degrees from New York University Medical School. His postgraduate experience was accrued at Harvard Medical School, the National Institutes of Health and Cornell Medical Center. Profile
TWST: Could you begin with an overview of your coverage at Bear,

Stearns?

Dr. Samad: Our group focuses on the small to mid-cap biotechnology

space, and that means different things at different